Spectrum Pharmaceuticals Provides BLA Filing Update for ROLONTIS® (eflapegrastim)

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) announced today that due to the U.S. Food and Drug Administrations (FDA) request for additional manufacturing-related information for ROLONTIS, the company has voluntarily withdrawn its Biologics License Application (BLA).